Swedish Orphan Biovitrum
286.2 SEK +0.99%3 investors are following this company
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Revenue
22.12B
EBIT %
18.38 %
P/E
38.31
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SOBI
Daily low / high price
282.8 / 287.8
SEK
Market cap
101.42B SEK
Turnover
12.12M SEK
Volume
42K
Financial calendar
General meeting
2024-05-14
Interim report
2024-07-16
Interim report
2024-10-24
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Investor | 34.7 % | 34.7 % |
Morgan Stanley Smith Barney | 9.9 % | 9.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Swedish Orphan Biovitrum AB: Sobi® får positivt CHMP-utlåtande som rekommenderar godkännande av efanesoctocog alfa för behandling en gång i veckan av hemofili A
Swedish Orphan Biovitrum AB: Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools